Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

This study is for adults aged 18 and over who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), specifically with the 'unmutated IGHV' feature. You must have already completed your first round of standard treatment and your doctors need to have been able to assess how well that treatment worked.

There are also some general health checks. You need to be generally well enough to take part and have good liver, kidney, blood, and heart health. Women who could become pregnant and men who are sexually active with women who could become pregnant will need to use effective contraception.

However, you cannot join if your cancer has changed into a more aggressive type, or if your cancer has affected your brain or spinal cord. Also, if you have certain serious infections (like uncontrolled hepatitis B or C, or HIV), major heart problems, or need ongoing strong medicines to suppress your immune system, you wouldn't be able to take part. People with a history of serious blood disorders like HLH or certain other cancers are also not suitable.

If you join this study, it will involve two main parts. First, a small group of participants will help doctors figure out the best dose of Surovatamig. This might mean starting at a slightly lower dose and then adjusting it. Once the optimal dose is found, the main part of the study begins. Here, you would be randomly placed into one of two groups: one group will receive Surovatamig as an injection under the skin, and the other group will be carefully monitored by doctors without receiving Surovatamig.

Taking part will involve regular visits to the hospital for check-ups, blood tests, and scans to monitor your health and how the treatment is working (or how your condition is progressing if you're in the observation group). The exact schedule and total duration of your participation will be explained in detail by the study team, but it will involve ongoing assessments as part of this longer-term study.